8 results on '"Schmid, Yasmin"'
Search Results
2. Seizures as a complication of recreational drug use: Analysis of the Euro-DEN Plus data-set
- Author
-
Anseeuw, Kurt, Badaras, Robertas, Bonnici, Jeffrey, Brvar, Miran, Caganova, Blazena, Ceschi, Alessandro, Eyer, Florian, Galicia, Miguel, Geith, Stefanie, Gillebeert, Johan, Grenc, Damjan, Gorozia, Ketevan, Jaffal, Karim, Jürgens, Gesche, Kabata, Piotr Maciej, Kennedy, Iarlaith, Konstari, Jutta, Kutubidze, Soso, Laubner, Gabija, Liakoni, Evangelia, Liechti, Matthias E., Lyphout, Cathelijne, Mégarbane, Bruno, Miró, Òscar, Moughty, Adrian, Müller, Laura, O'Connor, Niall, Paasma, Raido, Perez, Juan Ortega, Perminas, Marius, Persett, Per Sverre, Põld, Kristiina, Puiguriguer, Jordi, Radenkova-Saeva, Julia, Rulisek, Jan, Schmid, Yasmin, Scholz, Irene, Sopirala, Radhika, Surkus, Jonas, Toth, Ibolya, Vallersnes, Odd Martin, Vigorita, Federico, Waldman, Wojciech, Waring, W. Stephen, Zacharov, Sergej, Wolfe, Caitlin E., Wood, David M., Dines, Alison, Whatley, Benjamin P., Yates, Christopher, Heyerdahl, Fridtjof, Hovda, Knut Erik, Giraudon, Isabelle, and Dargan, Paul I. more...
- Published
- 2019
- Full Text
- View/download PDF
Catalog
3. Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects
- Author
-
Vizeli, Patrick, Schmid, Yasmin, Prestin, Katharina, Meyer zu Schwabedissen, Henriette E., and Liechti, Matthias E.
- Published
- 2017
- Full Text
- View/download PDF
4. Effects of methylphenidate and MDMA on appraisal of erotic stimuli and intimate relationships
- Author
-
Schmid, Yasmin, Hysek, Cédric M., Preller, Katrin H., Bosch, Oliver G., Bilderbeck, Amy C., Rogers, Robert D., Quednow, Boris B., and Liechti, Matthias E.
- Published
- 2015
- Full Text
- View/download PDF
5. Sex differences in the pharmacology of itch therapies—a narrative review.
- Author
-
Schmid, Yasmin, Navarini, Alexander, Thomas, Zita-Rose Manjaly, Pfleiderer, Bettina, Krähenbühl, Stephan, and Mueller, Simon M
- Subjects
- *
ITCHING , *PHARMACOLOGY , *DRUG side effects , *GENDER , *BODY composition , *SEROTONIN uptake inhibitors - Abstract
Chronic itch is the most common skin-related condition, associated with a high psychosocial and economic burden. In recent years, increasing evidence of sex differences in the perception, clinical presentation and treatment requirements of itch points towards potential benefits when using sex-adapted therapies. It is well-known that body composition, absorption, metabolism, elimination and adverse drug reactions (ADRs) differ between sexes, but only little is known about the impact of sex in the pharmacology of itch treatments, which could help to rationalise sex-adapted treatment strategies. To evaluate and review sex effects in the pharmacokinetics and /-dynamics of drugs used to treat itch. In this narrative review we performed a PubMed and MEDLINE (Ovid) search using the terms (itch OR pruritus) AND (gender OR sex) AND (drug OR medication OR pharmacokinetics OR pharmacodynamics). Additional searches were performed for the topical and systemic drugs recommended by the European Guideline on Chronic Pruritus. We found numerous reports with variable levels of evidence of sex effects with respect to the pharmacokinetics and/or pharmacodynamics of 14 drug classes used for the treatment of itch, including a total of 19 systemic and 3 topical drugs. Women seem to present higher plasma levels of several drugs used in itch treatment, including tri- and tetracyclic antidepressants (e.g. doxepin, amitriptyline, mirtazapine), serotonin reuptake inhibitors (e.g. paroxetine, sertraline, fluoxetine), immunosuppressive drugs (e.g. cyclosporine, mycophenolate mofetil), serotonin receptor antagonists (e.g. ondansetron) and betablockers (e.g. propranolol). Adverse drug reactions (ADRs) were generally more common in women. Being female was reported to be an independent risk factor for QTc-prolongation associated with antihistamines and tetracyclic antidepressants. Additionally, women seem to be more prone to sedative effects of antihistamines, and to suffer from a higher frequency as well as severity of side effects with systemic calcineurin inhibitors, opioid agonists, and opioid antagonists. Women were also sensitised more often to topically applied drugs. Of note, apart from only one experimental study with capsaicin, none of these reports were designed specifically to assess the effect of sex (and gender) in the treatment of itch. Our review supports previous reports that sex is of importance in the pharmacokinetics and /-dynamics of several drugs used to treat itch although those drugs were mostly evaluated for non-itch indications. However, the results are limited by methodological limitations evident in most studies such as underrepresentation of women in clinical trials. This emphasises the need to study the impact of sex (and gender) in future itch trials to yield better outcomes and prevent ADRs in both sexes. [ABSTRACT FROM AUTHOR] more...
- Published
- 2019
- Full Text
- View/download PDF
6. A non-hallucinogenic LSD analog with therapeutic potential for mood disorders.
- Author
-
Lewis, Vern, Bonniwell, Emma M., Lanham, Janelle K., Ghaffari, Abdi, Sheshbaradaran, Hooshmand, Cao, Andrew B., Calkins, Maggie M., Bautista-Carro, Mario Alberto, Arsenault, Emily, Telfer, Andre, Taghavi-Abkuh, Fatimeh-Frouh, Malcolm, Nicholas J., El Sayegh, Fatema, Abizaid, Alfonso, Schmid, Yasmin, Morton, Kathleen, Halberstadt, Adam L., Aguilar-Valles, Argel, and McCorvy, John D. more...
- Abstract
Hallucinations limit widespread therapeutic use of psychedelics as rapidly acting antidepressants. Here we profiled the non-hallucinogenic lysergic acid diethylamide (LSD) analog 2-bromo-LSD (2-Br-LSD) at more than 33 aminergic G protein-coupled receptors (GPCRs). 2-Br-LSD shows partial agonism at several aminergic GPCRs, including 5-HT 2A , and does not induce the head-twitch response (HTR) in mice, supporting its classification as a non-hallucinogenic 5-HT 2A partial agonist. Unlike LSD, 2-Br-LSD lacks 5-HT 2B agonism, an effect linked to cardiac valvulopathy. Additionally, 2-Br-LSD produces weak 5-HT 2A β-arrestin recruitment and internalization in vitro and does not induce tolerance in vivo after repeated administration. 2-Br-LSD induces dendritogenesis and spinogenesis in cultured rat cortical neurons and increases active coping behavior in mice, an effect blocked by the 5-HT 2A -selective antagonist volinanserin (M100907). 2-Br-LSD also reverses the behavioral effects of chronic stress. Overall, 2-Br-LSD has an improved pharmacological profile compared with LSD and may have profound therapeutic value for mood disorders and other indications. [Display omitted] • 2-Br-LSD is a 5-HT 2A partial agonist but lacks 5-HT 2B agonism • 2-Br-LSD lacks head-twitch responses and tolerance; blocks psychedelics • 2-Br-LSD treatment promotes neuronal structural plasticity dependent on 5-HT 2A • 2-Br-LSD produces active coping behavior and reverses chronic stress deficits Lewis et al. perform an extensive pharmacological characterization of 2-Br-LSD, finding distinct aminergic GPCR polypharmacology, including 5-HT 2A partial agonism and lack of psychedelic-like effects in vivo. Further, 2-Br-LSD induces dendritogenesis and spinogenesis in vitro while promoting active coping behavior in vivo , effects dependent on 5-HT 2A activation. [ABSTRACT FROM AUTHOR] more...
- Published
- 2023
- Full Text
- View/download PDF
7. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.
- Author
-
Schmid, Yasmin, Enzler, Florian, Gasser, Peter, Grouzmann, Eric, Preller, Katrin H., Vollenweider, Franz X., Brenneisen, Rudolf, Müller, Felix, Borgwardt, Stefan, and Liechti, Matthias E.
- Subjects
- *
LSD (Drug) , *DRUG side effects , *PEOPLE with schizophrenia , *PSYCHOTHERAPY , *NEURAL stimulation , *RANDOMIZED controlled trials , *HEALTH outcome assessment ,PSYCHIATRIC research - Abstract
Background After no research in humans for >40 years, there is renewed interest in using lysergic acid diethylamide (LSD) in clinical psychiatric research and practice. There are no modern studies on the subjective and autonomic effects of LSD, and its endocrine effects are unknown. In animals, LSD disrupts prepulse inhibition (PPI) of the acoustic startle response, and patients with schizophrenia exhibit similar impairments in PPI. However, no data are available on the effects of LSD on PPI in humans. Methods In a double-blind, randomized, placebo-controlled, crossover study, LSD (200 μg) and placebo were administered to 16 healthy subjects (8 women, 8 men). Outcome measures included psychometric scales; investigator ratings; PPI of the acoustic startle response; and autonomic, endocrine, and adverse effects. Results Administration of LSD to healthy subjects produced pronounced alterations in waking consciousness that lasted 12 hours. The predominant effects induced by LSD included visual hallucinations, audiovisual synesthesia, and positively experienced derealization and depersonalization phenomena. Subjective well-being, happiness, closeness to others, openness, and trust were increased by LSD. Compared with placebo, LSD decreased PPI. LSD significantly increased blood pressure, heart rate, body temperature, pupil size, plasma cortisol, prolactin, oxytocin, and epinephrine. Adverse effects produced by LSD completely subsided within 72 hours. No severe acute adverse effects were observed. Conclusions In addition to marked hallucinogenic effects, LSD exerts methylenedioxymethamphetamine-like empathogenic mood effects that may be useful in psychotherapy. LSD altered sensorimotor gating in a human model of psychosis, supporting the use of LSD in translational psychiatric research. In a controlled clinical setting, LSD can be used safely, but it produces significant sympathomimetic stimulation. [ABSTRACT FROM AUTHOR] more...
- Published
- 2015
- Full Text
- View/download PDF
8. Emergency department presentations related to acute toxicity following recreational use of cannabis products in Switzerland.
- Author
-
Schmid, Yasmin, Scholz, Irene, Mueller, Laura, Exadaktylos, Aristomenis K., Ceschi, Alessandro, Liechti, Matthias E., and Liakoni, Evangelia
- Subjects
- *
HOSPITAL emergency services , *MARIJUANA , *CHEST pain , *MENTAL health services , *PANIC attacks , *CRITICAL care medicine - Abstract
Background: Concomitant use of cannabis and other psychoactive substances is common and it is often difficult to differentiate its acute effects from those of other substances. This study aimed to characterize the acute toxicity of cannabis with and without co-use of other substances.Methods: Retrospective analysis of cases presenting at the emergency departments of three large hospitals in Switzerland due to acute toxicity related to cannabis recreational use.Results: Among 717 attendances related to acute cannabis toxicity, 186 (26 %) were due to use of cannabis alone. The median patient age was 26 years (range 14-68), and 73 % were male. Commonly reported symptoms/signs in lone-cannabis cases included nausea/vomiting (26 %), palpitations (25 %), anxiety (23 %), and chest pain (15 %); there were no fatalities and most intoxications were of minor severity (61 %). Most patients (83 %) using cannabis alone were discharged from the emergency department, 8 % were referred to psychiatric, and two (1 %) to the intensive care; severe complications included psychosis (7 %), coma (6 %), and seizures (5 %) and one patient (<1 %) required intubation. Lone-cannabis patients presented more often with palpitations, anxiety, panic attacks, and chest pain than patients in the co-use group, whereas the latter presented more often with impaired consciousness, agitation, respiratory depression and hallucinations, and were more often admitted to psychiatric or intensive care.Conclusion: Intoxication with cannabis alone was mostly associated with minor toxicity. Nevertheless, severe complications and cases requiring admission to intensive or psychiatric care were also reported, which indicates that intoxication with cannabis alone does not exclude considerable health risks. [ABSTRACT FROM AUTHOR] more...- Published
- 2020
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.